Literature DB >> 19769440

Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?

Elaine Kingwell, Helen Tremlett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19769440     DOI： 10.1586/ern.09.76

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN： 1473-7175            Impact factor:   4.618


× No keyword cloud information.
  4 in total

1.  A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Authors:  Afsaneh Shirani; Gregory F Wu; Caterina Giannini; Anne H Cross
Journal:  BMJ Case Rep       Date:  2018-06-28

2.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

3.  Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.

Authors:  Gary Bloomgren; Bjørn Sperling; Kimberly Cushing; Madé Wenten
Journal:  Ther Clin Risk Manag       Date:  2012-06-20       Impact factor: 2.423

Review 4.  Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports.

Authors:  Judith U Cope; Gregory H Reaman; Joseph M Tonning
Journal:  Sarcoma       Date:  2015-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.